https://wnbfactory.com/images/totoslot138/ https://wnbfactory.com/images/slot303/ https://wnbfactory.com/images/totoslot4d/
Drug Pricing – Pacific Research Institute

Drug Pricing

Commentary

Read the latest on drug innovation

How The FDA’s Sunscreen Skepticism Burns Americans

Every day, nearly 10,000 people in the United States are diagnosed with skin cancer. The good news is that applying sunscreen can substantially reduce a person’s risk of getting skin cancer. The bad news is that the federal government is doing its best to keep effective sunscreens out of the hands of ...
Commentary

Read the latest on drug pricing

Insulin Prices Fall, Democrats Respond With Denial

For years, the left’s campaign to dictate the price of prescription drugs has focused on one medicine above all others — insulin. The hormone was discovered more than a century ago by Canadian doctor Frederick Banting and his medical student Charles Best. They famously sold their patent to the University of ...
Commentary

Don’t Import British Methods For Rationing Access To Drugs

Earlier this year, European authorities recommended approval of tofersen, a new drug that treats a rare genetic form of amyotrophic lateral sclerosis, or ALS. That decision came nearly a year after American regulators granted the drug accelerated approval. Patients with that rare form of ALS in England aren’t so lucky. The National Institute for ...
Commentary

Read the latest on drug pricing

Inflation Reduction Act Will Destroy Drug Access

Last month at a White House event, President Joe Biden and Sen. Bernie Sanders, I-Vt., took a victory lap for supposedly having “beat Big Pharma” through drug-pricing provisions in the Inflation Reduction Act. Beaming with pride, they hailed new powers for Medicare to “negotiate” drug prices as a historic achievement. But their self-congratulation rests ...
Drug Pricing

NEW BRIEF: JAMA Study Justifying Drug Price Controls Deeply Flawed, Patient Health Jeopardized if Findings Implemented

SACRAMENTO – A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute analyzes a Journal of the American Medical Association (JAMA) study cited by Sen. Bernie Sanders (I-Vermont) to justify drug price controls, finding it was deeply flawed and would put ...
Commentary

Read the latest on pharmaceutical benefit managers

Biosimilars could save the healthcare system billions

Cost Plus Drug Company CEO Mark Cuban recently pointed out that self-insured businesses could save over $70,000 per employee annually by getting their workers to switch from AbbVie’s blockbuster anti-inflammatory treatment Humira to a lower-cost biosimilar called Yusimry. Humira has a list price of roughly $7,000 per month. Since it lost market exclusivity last year, nine nearly identical copycats have hit ...
Commentary

Congress Has A Big Chance To Investigate A Financial Threat To Patients

Following an enormous cyberattack on a subsidiary of UnitedHealth Group, the Senate Finance Committee has called the company’s CEO, Andrew Witty, to testify on April 30th. The hackers stole millions of medical records, which reflects badly on the company’s ability to protect patients. But while members of Congress are grilling Witty about the ...
Commentary

Read the latest on prescription drug pricing

Biden, Sanders Took on ‘Big Pharma’ and Patients Lost

Speaking at a White House event with Sen. Bernie Sanders, I-Vt., very recently, President Biden crowed about his rapidly progressing scheme to impose price controls on prescription drugs. “Finally — finally we beat Big Pharma,” he said to Sanders. Unfortunately for Americans — and indeed, patients everywhere — the Democrats’ assault on the drug industry ...
Commentary

Read the latest on US drug pricing

Global Collaboration on Reference Models Will Further Depersonalize Healthcare

By Sally Pipes & Wayne Winegarden  Question: What’s worse than government bureaucrats in Washington declaring the value of your medicine? Answer: Bureaucrats from Boston, London, Ottawa and Diemen establishing that value. Unfortunately, this is not a joke. It is the direction that the Institute for Clinical and Economic Review is ...
Commentary

Lawsuit Against Drug Company Could Quash Future Cures

Like most pharmaceutical companies, Gilead Sciences Inc. devotes a huge amount of time and money to making sure its products are safe for patients. The U.S. Food and Drug Administration approved its drugs to fight HIV, and these medications have worked remarkably well. It then developed the next generation of ...
Commentary

Read the latest on drug innovation

How The FDA’s Sunscreen Skepticism Burns Americans

Every day, nearly 10,000 people in the United States are diagnosed with skin cancer. The good news is that applying sunscreen can substantially reduce a person’s risk of getting skin cancer. The bad news is that the federal government is doing its best to keep effective sunscreens out of the hands of ...
Commentary

Read the latest on drug pricing

Insulin Prices Fall, Democrats Respond With Denial

For years, the left’s campaign to dictate the price of prescription drugs has focused on one medicine above all others — insulin. The hormone was discovered more than a century ago by Canadian doctor Frederick Banting and his medical student Charles Best. They famously sold their patent to the University of ...
Commentary

Don’t Import British Methods For Rationing Access To Drugs

Earlier this year, European authorities recommended approval of tofersen, a new drug that treats a rare genetic form of amyotrophic lateral sclerosis, or ALS. That decision came nearly a year after American regulators granted the drug accelerated approval. Patients with that rare form of ALS in England aren’t so lucky. The National Institute for ...
Commentary

Read the latest on drug pricing

Inflation Reduction Act Will Destroy Drug Access

Last month at a White House event, President Joe Biden and Sen. Bernie Sanders, I-Vt., took a victory lap for supposedly having “beat Big Pharma” through drug-pricing provisions in the Inflation Reduction Act. Beaming with pride, they hailed new powers for Medicare to “negotiate” drug prices as a historic achievement. But their self-congratulation rests ...
Drug Pricing

NEW BRIEF: JAMA Study Justifying Drug Price Controls Deeply Flawed, Patient Health Jeopardized if Findings Implemented

SACRAMENTO – A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute analyzes a Journal of the American Medical Association (JAMA) study cited by Sen. Bernie Sanders (I-Vermont) to justify drug price controls, finding it was deeply flawed and would put ...
Commentary

Read the latest on pharmaceutical benefit managers

Biosimilars could save the healthcare system billions

Cost Plus Drug Company CEO Mark Cuban recently pointed out that self-insured businesses could save over $70,000 per employee annually by getting their workers to switch from AbbVie’s blockbuster anti-inflammatory treatment Humira to a lower-cost biosimilar called Yusimry. Humira has a list price of roughly $7,000 per month. Since it lost market exclusivity last year, nine nearly identical copycats have hit ...
Commentary

Congress Has A Big Chance To Investigate A Financial Threat To Patients

Following an enormous cyberattack on a subsidiary of UnitedHealth Group, the Senate Finance Committee has called the company’s CEO, Andrew Witty, to testify on April 30th. The hackers stole millions of medical records, which reflects badly on the company’s ability to protect patients. But while members of Congress are grilling Witty about the ...
Commentary

Read the latest on prescription drug pricing

Biden, Sanders Took on ‘Big Pharma’ and Patients Lost

Speaking at a White House event with Sen. Bernie Sanders, I-Vt., very recently, President Biden crowed about his rapidly progressing scheme to impose price controls on prescription drugs. “Finally — finally we beat Big Pharma,” he said to Sanders. Unfortunately for Americans — and indeed, patients everywhere — the Democrats’ assault on the drug industry ...
Commentary

Read the latest on US drug pricing

Global Collaboration on Reference Models Will Further Depersonalize Healthcare

By Sally Pipes & Wayne Winegarden  Question: What’s worse than government bureaucrats in Washington declaring the value of your medicine? Answer: Bureaucrats from Boston, London, Ottawa and Diemen establishing that value. Unfortunately, this is not a joke. It is the direction that the Institute for Clinical and Economic Review is ...
Commentary

Lawsuit Against Drug Company Could Quash Future Cures

Like most pharmaceutical companies, Gilead Sciences Inc. devotes a huge amount of time and money to making sure its products are safe for patients. The U.S. Food and Drug Administration approved its drugs to fight HIV, and these medications have worked remarkably well. It then developed the next generation of ...
Scroll to Top